Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience
| Autor: | Andrea Torres, Yasmeen Golzar, Juan Del Cid Fratti, Hashim Mann, Tauseef Akhtar, Setri Fugar, Chineme Nwaichi, Alok Uprety, Jishanth Mattumpuram |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Gastrointestinal bleeding Hemorrhage 030204 cardiovascular system & hematology Coronary artery disease 03 medical and health sciences 0302 clinical medicine Rivaroxaban Internal medicine Atrial Fibrillation medicine Humans 030212 general & internal medicine Outpatient pharmacy Aged Retrospective Studies Aspirin business.industry Anticoagulants Atrial fibrillation Retrospective cohort study Odds ratio Middle Aged medicine.disease Stroke Female Warfarin Cardiology and Cardiovascular Medicine business Factor Xa Inhibitors medicine.drug |
| Zdroj: | International Journal of Cardiology. 320:78-82 |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2020.06.032 |
| Popis: | Background Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the treatment of non-valvular atrial fibrillation (NVAF). Data related to the risk factors associated with rivaroxaban-induced bleeding in patients with NVAF remain scarce in the community setting. We sought to investigate these bleeding risk factors in a racially diverse patient population. Methods We conducted a single-center, retrospective study based on a chart review of patients who received rivaroxaban from our outpatient pharmacy from January 2015 to April 2018 for NVAF. Any reported bleeding event (BE) was recorded as either major or minor bleeding event. Demographic and clinical data were collected and analyzed. Results Of the 327 patients included in our analysis, 105 (32%) were female, and the mean age was 62 ± 12 years. Among the included patients, 176 (54%) patients were black, 71 (22%) were white, 51 (15.6%) were Hispanic, 13 (4%) were Asian, and 15 (4.6%) belonged to other races. 89 (27.2%) of the patients had co-prescription of aspirin. A total of 24 (7.3%) patients developed BE, out of which 9 (2.7%) patients had a major BE, and 15 (4.5%) patients had minor BE. Non-fatal gastrointestinal bleeding and epistaxis were the most common type of BE. On multivariable analysis, concurrent aspirin use (81 to 325 mg) (P = 0.03; odds ratio (OR) 2.60 [1.08–6.28]) and increasing age (P = 0.00; OR 1.06 [1.01–1.11]) were independent predictors of BE. Conclusion In community practice, aspirin co-prescription is common among NVAF patients prescribed rivaroxaban. Increasing age and concurrent aspirin use are independent predictors of BE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect